The predictive role of Bcl-2 expression in operable locally advanced or metastatic gastric carcinoma

Journal of B.U.ON.

Volumn 17, Issue 1, 2012, Pages 106-109

  Yildirim, Mustafa ^a   Suren, D ^b   Goktas, S ^a   Dilli, U D ^a   Kaya, C ^a   Copuroglu, R ^b   Yildiz, M ^a   Sezer, C ^b  

^a Antalya Education and Research Hospital   (Turkey)

^b Antalya Education and Research Hospital ^*  (Turkey)

Author keywords

Bcl 2; Chemotherapy; Gastric cancer; Prediction of response

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; PROTEIN BCL 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELLULAR DISTRIBUTION; CONTINUOUS INFUSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STOMACH CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS;

EID: 84859864555     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett 1998; 102-103: 227-234. (Pubitemid 29021225)
2. Stewart BW, Kleihues P (Eds): World Cancer Report. IARC Press, Lyon, 2003.
3. Tuncer AM. Cancer control in Turkey. TC. Ministry of Health, Ankara 2009 (in Turkish).
4. McDonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
5. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168. (Pubitemid 27112884)
6. Van Cutsem E, Moisenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4917.
7. Ayhan A, Yasui W, Yokozaki H, Seto M, Ueda R, Tahara E. Loss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas. Jpn J Cancer Res 1994; 85: 584-591. (Pubitemid 24191233)
8. Klein RF, Vollmers HP, Muller-Hermelink HK, Different expression of bcl-2 in diffuse and intestinal type stomach carcinomas. Oncol Rep 1994; 69: 943-946.
9. Aizawa K, Ueki K, Suzuki S et al. Apoptosis and bcl-2 expression in gastric carcinoma: correlation with clinicopathological variables, p53 expression, cell proliferation and prognosis. Int J Oncol 1999; 14: 85-91.
10. Protrka Z, Djuric J, Protrka O, Arsenijevic S. The possible role of Bcl-2 expression of tumors of the uterine cervix. J BUON 2010; 15: 323-329.
11. Hyeon Kook Lee, Hye Seung Lee, Han-Kwang Yang et al. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis 2003; 18: 518-525.
12. Saegusa M, Takano Y, Okayasu I. Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol 1995; 121: 357-363.
13. Perrone G, Vincenzi B, Santini D et al. Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. Cancer Lett 2004; 208: 227-234. (Pubitemid 38624165)
14. Pezzella F, Turley H, Kuzu I et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694. (Pubitemid 23252262)
15. Silvestrini R, Veneroni S, Daidone MG et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504. (Pubitemid 24111005)
16. Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995; 72: 1324-1329.
17. Manne U, Myers RB, Moron C et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997; 74: 346-358. (Pubitemid 27321807)
18. Sahan E, Tetikkurt US, Balci C, Igdem AA, Gultekin SE, Erdogan N. Evaluation P53 and Bcl-2 expression with Ki-67 proliferation index in prostatic adenocarcinoma. Their correlation with histopathological and clinical prognostic factors. Türk Üroloji Dergisi 2003; 29: 250-257. (Pubitemid 37203291)
19. Kirkina V, Joos S, Zo M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229-249. (Pubitemid 38281277)
20. Marzo I, Naval J. Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol 2008; 76: 939-946.
21. Kim R, Emi M, Tanabe K, Toge T. Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer 2004; 101: 2177-2186. (Pubitemid 39458671)
22. Buchholz T, Davis DW, McConkey DJ et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003; 9: 33-41.
23. Jeonga SH, Junga JH, Hanb JH et al. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer 2010; 68: 288-294.